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Low-energy pulsed electromagnetic field (PEMF) therapy has been suggested as a promising therapy
to increase microcirculation, which is of great concern in patients with fibromyalgia. This study
evaluated the effectiveness of PEMF therapy on the treatment of fibromyalgia. A group of 108 women
with fibromyalgia were allocated to a 12-week treatment period with an active Bio-Electro-Magnetic-
Energy-Regulation (BEMER) device and a similar treatment period with an inactive device. Each
patient received active and sham treatments in a random order. Pain and stiffness were assessed on a
visual analog scale (VAS, scale 0–100mm), and functional status was assessed by the Fibromyalgia
Impact Questionnaire (FIQ). Mean VAS pain scores before the active and sham treatment periods
were 66 (SD22) and 63 (SD22), respectively. After treatment periods, mean VAS pain scores had
decreased significantly in active treatment, 12, 95% CI [18, 6], and in sham treatment, 11,
95% CI [17, 5]. Similarly, the decrease in stiffness and FIQ index after both treatments was
statistically significant. However, per-protocol analysis showed no differences between active and
sham treatments at any of the outcomes. This study demonstrated that low-energy PEMF therapy was
not efficient in reducing pain and stiffness or in improving functioning in women with fibromyalgia.
Bioelectromagnetics. 39:405–413, 2018. © 2018 Wiley Periodicals, Inc.
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INTRODUCTION
Fibromyalgia is a common syndrome, with a
prevalence of approximately 5% in women and 1%
in men [Vincent et al., 2013]. It is a condition of
soft tissue pain, subjective muscular stiffness, unre-
mitting fatigue, disturbed sleep, and cognitive dys-
function. Numerous possible mechanisms have been
postulated to cause fibromyalgia, such as pain
hypersensitivity [Gracely et al., 2002], hormonal
influences [Sadreddini et al., 2008; Cuatrecasas,
2009], neurotransmitter imbalances [Becker and
Schweinhardt, 2012], inflammation [Kadetoff et al.,
2012], sleep dysfunction [Moldofsky, 2010; Hussain
et al., 2011], mitochondrial dysfunction [Pieczenik
and Neustadt, 2007; Gardner and Boles, 2011],
small fiber neuropathy [Caro and Winter, 2015],
and central sensitivity syndrome [Yunus, 2007;
Burgmer et al., 2009; Clauw et al., 2011]. Patients
with fibromyalgia have been reported as having
lower peripheral circulation compared to controls,
which has been assumed to be due to lower
capillary density as well as due to altered autonomic
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regulation [Morf et al., 2005; Choi and Kim, 2015].
Research also suggests that the arteries of patients
with fibromyalgia feel stiffer and are less efficient
than those of healthy controls [Lee et al., 2011],
which may lead to poor circulation and a less
efficient blood supply to connective tissues. The
exact pathomechanism of fibromyalgia is still un-
known, and there is no specific treatment for
fibromyalgia.
Electric current therapies have been shown to
significantly relieve pain in the short term in
fibromyalgia. These include both transcutaneous
and percutaneous electrical nerve stimulation [Car-
bonario et al., 2013; Dailey et al., 2013; Mutlu
et al., 2013; Salazar et al., 2017] and a combination
of interferential current and ultrasound (US)
[Almeida et al., 2003]. Pulsed electromagnetic
fields (PEMF), which are one application of magne-
totherapy, have also been used for the management
of a variety of musculoskeletal conditions [Markov,
2015]. PEMFs differ from other electrotherapy
modalities primarily because they are a subthresh-
old, low-power, and low-frequency electromagnetic
waveform [Thomas et al., 2007]. PEMF has shown
beneficial effects on osteoarthritis [Li et al., 2013;
Bagnato et al., 2016], as well as on peripheral
blood circulation [Sun et al., 2016] and healing of
skin ulcers [Ieran et al., 1990] with a device
producing magnetic field intensity of 2.8mT. How-
ever, not all findings on the topic concur [Gupta
et al., 2009; Hug and R€o€osli, 2012]. In patients
with fibromyalgia, PEMF with a portable headset
device has not shown significant effects on pain
[Shupak et al., 2006; Thomas et al., 2007], whereas
the application of a whole-body PEMF mat has
been suggested to decrease pain in fibromyalgia
patients [Sutbeyaz et al., 2009].
A PEMF system called Bio-Electro-Magnetic-
Energy Regulation (BEMER, Innomed International,
Triesen, Lichtenstein) has been reported as increasing
vasomotion and microcirculation for improved organ
blood flow using a series of half-wave–shaped
sinusoidal intensity variations [Bohn et al., 2013;
Klopp et al., 2013]. To date, however, there are no
randomized controlled trials (RCT) where the effect
of this PEMF device treatment on pain or other
symptoms of fibromyalgia has been studied. There-
fore, we wanted to test whether low-energy PEMF
might have positive responses on symptoms in
patients with fibromyalgia possibly via increased
microcirculation. The purpose of this study was to
investigate whether PEMF therapy can decrease pain




This study was a randomized, double-blind,
placebo-controlled crossover study (NCT02310386;
BEMER in the Treatment of Pain in Fibromyalgia).
Recruitment and data collection took place between
April 2014 and December 2016. The participants
were adult women with fibromyalgia. The study
protocol was approved by the Ethics Committee of
the Central Finland Health Care District, and complies
with the Declaration of Helsinki. All participants gave
their written informed consent prior to enrollment,
and were free to withdraw from the study at any time
for any reason without consequences for the care
provided.
Participant Recruitment
The participants for this study were recruited
through the patient record of the Central Finland
Central Hospital. A database search was carried out
for patients who had been visiting a specialist between
May 2007 and November 2015, and who were
diagnosed as having M79.0 (Rheumatism, unspeci-
fied), M79.1 (Myalgia), or M79.7 (Fibromyalgia)
according to the International Classification of Dis-
eases (ICD). As a result of this search, 1042 patients
with established or potential fibromyalgia were sent
information about the study and an invitation to
participate. A total of 286 subjects indicated their
interest in the study, and they were sent a health
questionnaire with a prepaid return envelope to assess
their preliminary eligibility to participate in the study.
In addition to patients’ sociodemographic and occupa-
tional data, the health questionnaire addressed medical
condition, current medication, sleep quality and mood
in the last week, alcohol and tobacco use, and
treatments received in the previous three months.
Eligibility criteria included being a woman aged 18–
60 with diagnosed fibromyalgia, persistent moderate
or severe pain for more than 12 months, and a pain
intensity of 5 or more on a scale of 0–10 within the
last seven days. Twenty-three respondents declined to
take part in the trial and 263 respondents returned the
questionnaire, 133 of which were excluded from the
study due to exclusion criteria. The exclusion criteria
were as follows: an inflammatory rheumatic disease,
another chronic pain disease besides fibromyalgia,
mental illness, drug/substance abuse, smoking, intel-
lectual disability, and pregnancy or breastfeeding. The
remaining 130 patients were invited to Central
Finland Central Hospital for a visit to a physiatrist,
who performed a clinical examination to ensure that
the participants would not have any limitations to
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their study participation and to verify the presence of
fibromyalgia. Fibromyalgia was defined according to
the American College of Rheumatology’s (ACR)
classification criteria, and it was confirmed if the
patient had widespread pain for at least three months
and if she had 11 or more tender points out of 18
specified points [Wolfe et al., 1997]. Fourteen patients
did not meet the eligibility criteria during the clinical
examinations, and eight participants withdrew from
the study, thus leaving a sample of 108 participants
for the study. Figure 1 shows the participant recruit-
ment.
Randomization and Blinding
The 108 patients who fulfilled the inclusion
criteria were assigned to treatment with real electro-
magnetic field devices or with sham electromagnetic
field devices according to a computer-generated
randomization procedure with 30 consecutive bal-
anced blocks of four patients (two active, two sham).
Patients, the attending physiatrist (JY), device deliv-
erer (JM), outcome assessor (AH), and statistician
(HK) were all blinded to the treatment group assign-
ment.
Treatments
In the first treatment period, 57 patients assigned
to active treatment and 51 patients assigned to sham
treatment were instructed to use the electromagnetic
field device (BEMER) for 12 weeks. The device
consisted of a pulse generator and field generation via
flat, flexible electric coils, that is, a mat the patients
are asked to lie down on twice a day: soon after
waking up in the morning and before bedtime. The
patients were advised, as suggested by the manufac-
turer, to drink a glass of noncarbonated lukewarm
water prior to the treatments in order to enhance
treatment effects.
Figure 2 shows the general setup used for
treatment application. The device produces a weak,
low-frequency, pulsed electromagnetic field with a
signal consisting of five series of pulses of half-wave-
shaped sinusoidal variations. The pulse structure
includes the sequences 1–5 as follows. Sequence 1:
0mT for 1–3 s; sequence 2: 3–12mT, a “base signal”
for 12–16 s with a pulse frequency of 33.3Hz (pulse
width 30ms); sequence 3: 30–150mT, an “additional
signal” with a pulse width of 100–200ms; sequence
4: sequences 2 and 3 are repeated 8–10 times;
sequence 5: 0mT for 1–3 s. Amplitudes of the
individual pulses within the sequence follow an
exponential function with an arcuate pattern. After
2min, the magnetic field changes its polarity [Gleim
and Klopp, 2014]. For this study, the duration of
signal sequences was set to a period of 8min. The mat
had six circular coils (diameter 14 cm) in two rows.
The distance between rows was 30 cm from center to
center of the coils. Longitudinally, the coils had
distances 47 cm and 37 cm from each other. Since the
coil geometry was very simple, the field distributions
could be easily calculated. The current in the coil was
adjusted to give a flux density of 50mT in the center
of the coil and in the plane of the coil (approximately
on the mat). According to the manufacturer, the
maximum flux density (peak value) is about 50mT,
which is roughly the same as the Earth’s magnetic
field. Graph (A) in Figure 3 shows the magnetic field
as a function of distance from the mat along the axis
of the coil, and graph (B) shows the variation of the
flux density at a height of 5 cm from the mat. As can
be seen, the field is practically localized within the
area of the coils. Figure 4 shows the flux density map:
the left edge is the axial symmetry axis (coil center),
and outer radius of the coil is 70mm. The border
between the blue and greenish area corresponds to
flux density, which is 50% of the flux density at the
center of the coil.
Prior to the beginning of the study, the manufac-
turer labeled the devices as active or inactive, and the
sealed code was given to only one investigator (SM)
to be opened after the final statistical analyses.
The active and inactive devices were identical in
Fig. 1. Flow chart of the recruitment process and inclusion of
participants.
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appearance, with sound and display indicator lights on
during the setup and treatment. The handheld device
with a light indicating that the magnetic field is on or
off was removed from the package that was given to
patients for therapy at home.
After the first treatment period in weeks 1–12,
there was a washout period in weeks 13–16, during
which there was no treatment and participants visited
the hospital in order to exchange the device for one
labelled the opposite of what it had been during the
first period, for a second treatment period in weeks
17–28. The participants kept a daily diary in which
they recorded the actual application of the electromag-
netic field therapy device and the use of drugs for the
treatment of fibromyalgia symptoms.
Outcome Measures
Patients were evaluated at inclusion as well as at
follow-up measurements after the first treatment
period, the washout period, and second treatment
period. The outcome measures were visual analog
scale assessments of pain and stiffness of the past
week ranging from 0 to 100mm [McCormack et al.,
1988]. In addition, all patients answered the Finnish
version of the validated Fibromyalgia Impact Ques-
tionnaire (FIQ) [Gauffin et al., 2012]. The FIQ is a
multidimensional self-administered questionnaire in-
cluding 10 questions evaluating physical function,
work status, depression, anxiety, sleep, pain, stiffness,
fatigue, and well-being. The resulting score (FIQ total
score), which indicates the impact of the disease on
quality of life, ranged from 0 (no impact) to 100
(maximum impact) [Burckhardt et al., 1991]. We used
the 10-item method for deriving a total score.
Sample Size
Before the study, the estimated sample size for
power calculation was determined with the goal of
measuring an improvement in the VAS pain score as
found in a previous study of fibromyalgia populations
[Sutbeyaz et al., 2009]. Power calculations indicated
that a sample of 110 patients (55 in each treatment),
Fig. 2. Treatment setup with the device comprising a pulse generator and mat for generating
a pulsed electromagnetic field.
Fig. 3. Variation of the flux density at a height of 5 cm from
the mat (A), and the magnetic field as a function of distance
from the mat along the axis of the coil (B).
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assuming a dropout rate of approximately 10%, would
provide an 80% (b¼ 0.20) chance of detecting a 40%
(a¼ 0.05) difference in improvement between the
active and sham treatments.
Statistical Analyses
Mean and standard deviations are given as
descriptive statistics. The main outcome variables
were analyzed according to the per-protocol analysis
principle by using random effect models. The models
were adjusted for period effect. The association
between use of active and treatment devices and the
changes in pain were examined with Pearson’s
correlation coefficient. The level of statistical signifi-
cance was set at a 0.05. Data were analyzed using
STATA 14.1 statistical software package (StataCorp,
College Station, TX).
RESULTS
Study Population and Baseline Characteristics
Baseline demographic characteristics are pre-
sented in Table 1. The 108 patients had a mean age of
47 10 (range 24–61) years and a mean body mass
index of 29 5 (range 18–44). The mean fibromyal-
gia illness duration, determined as the time since the
fibromyalgia diagnosis, was 7 7 (range 0–31) years.
The most commonly used medications to treat or
reduce the symptoms of fibromyalgia were analgesics.
Eighty-six patients (80%) were taking either prescrip-
tion or over-the-counter analgesics at the beginning of
the study. Ninety-two patients (85%) had one or more
comorbidities. The most common comorbidities were
different musculoskeletal problems such as osteoar-
thritis, spondylosis, and lower back pain (47%), lung
and respiratory diseases (29%), cardiovascular dis-
eases (22%), thyroid diseases (19%), neurological
disorders (15%), mild mental disorders (12%), aller-
gies (8%), and Type 1 or 2 diabetes (7%).
Dropout Rate and Harms
Of the 108 patients who started the treatments,
nine dropped out during the study. Four patients
dropped out during the active treatment period. The
reasons were the following: worsened previous back-
ache (n¼ 1) and unwilling to continue (n¼ 3). Five
patients dropped out during the sham treatment
period. The reasons for those dropouts were amplified
overall pain and worsened irritable bowel syndrome
(n¼ 1), lumbar herniated disc (n¼ 1), cervical herni-
ated disc surgery (n¼ 1), chronic pneumonia (n¼ 1),
and unwilling to continue (n¼1; Fig. 1). Of the
enrolled patients, 92% completed the study.
Considering the harms of the study, one patient
experienced an amplified overall pain sensation and
had worsened irritable bowel syndrome during the
sham treatment period. A 7-day treatment break was
used as a cure. After continuing the treatment with the
same sham device, the symptoms returned and the
Fig. 4. The flux density distribution of the coil. The left edge is the axial symmetry axis (coil
center) and the outer radius of the coil is 70 mm.
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patient was withdrawn from the study. No adverse
events occurred during the active treatment period.
Treatment Results
After the experiment, both active and sham
treatment showed a significant improvement in pain,
12, 95% CIs [18, 6] and 11 [17, 5]
respectively; stiffness, 9 [15, 4] and 11 [17,
5]; and FIQ 5 [8, 2] and 6 [9, 3]. The
baseline values and changes of pain, stiffness, and
FIQ after treatments are given in Table 2. There were
no significant differences at any of the outcome
measures between active and sham treatments
(Fig. 5).
Mean treatment compliance, measured as atten-
dance at all 168 planned, 8-min treatment sessions,
was 134 41 (80%) when using the active devices
and 131 44 (78%) when using the sham devices.
There was no correlation between the frequency of
using the device and a decrease in pain, being
r¼0.11, 95% CI [0.31, 0.10] in active treatments
and r¼0.10, 95%CI [0.31, 0.12] in sham treat-
ments.
DISCUSSION
To the best of our knowledge, this is the first
randomized, double-blind, sham-controlled study to
examine the effect of low-energy PEMF treatment on
pain, stiffness, and functional status in patients with
fibromyalgia. The study showed that the treatment
with an active device had no statistically significant
improvement in pain, stiffness, or FIQ index over the
sham treatment. All patients reported decreased pain,
stiffness, and FIQ ratings across time, an occurrence
describing the placebo effect. However, the reductions
of pain and stiffness values in VAS, in the range of
9–12mm, do not suggest clinical significance [Bird
and Dickson, 2001]. By the end of the study, the
patients still experienced severe pain and stiffness.
Treatment was well tolerated and no serious side effects
occurred. The treatment adherence was high (80%).
Our finding is contrary to that of a previous RCT
by Sutbeyaz et al. [2009] and a pilot study by Paolucci
et al. [2016], showing that both PEMF and a non-
pulsed magnetic field delivered by whole-body mats
had beneficial effects on fibromyalgia patients’ dis-
ease impact and pain intensity after somewhat short
treatment periods. Instead, our finding is in line with
another RCT by Alfano et al. [2001], who found no
improvement from static magnetic sleep pads on
functional status measured by FIQ, although active
magnetic sleep pads decreased pain intensity signifi-
cantly more than inactive pads did in the control
group. However, the electromagnetic signals, dosage
of the treatments, and study durations (three weeks in
Sutbeyaz et al. [2009]; 4 weeks in Paolucci et al.
[2016]; and 6 months in Alfano et al. [2001]) were
different than those in the present study. In addition,
the results of the above-mentioned previous studies
should be interpreted with caution due to the small
sample sizes in each treatment arm, which increases
the possibility that positive results are due to chance.
TABLE 1. Demographic Characteristics of the Patients With
Fibromyalgia
Variables N¼ 108
Age (years) 47 (10)
Height (cm) 164 (6)
Weight (kg) 77.6 (14.4)
Body mass index (kg/m2) 28.9 (5.4)
Working status, n (%)
Working 53 (49)
Not working 49 (45)
Retired 6 (6)
Time since fibromyalgia diagnosis (years) 7.1 (7.0)
Tender points score (0–18) 16.2 (1.9)
Beighton total score (0–9) 3.2 (2.8)
Pain, past week, VAS (0–100mm) 70 (17)
Stiffness, past week, VAS (0–100mm) 65 (22)
Sleep qualitya, past week, VAS (0–100mm) 33 (26)
Mooda, past week, VAS (0–100mm) 29 (22)





Muscle relaxants 21 (19)
Antidepressants 49 (45)
Values are means (SD) or n (%).
aNegative number indicates a lower quality of sleep or mood.
Fig 5. Changes in pain, stiffness, and Fibromyalgia Impact
Questionnaire index after 12 weeks of treatments with active
device and sham device. The square denotes mean and the
bars denote 95% confidence intervals.
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However, some evidence has been found that
exposure to electromagnetic fields affects pain sensi-
tivity (nociception) and pain inhibition (analgesia) in
some conditions [Del Seppia et al., 2007]. The
inventors of the device used in this study suggest that
functional improvements in microcirculation, lym-
phatic flow, and the immune system could stimulate
local and higher homeostatic autoregulatory mecha-
nisms [Gleim and Klopp, 2014]. However, from a
physical point of view the effect of magnetic fields on
human cells is via electromagnetic interaction. For
static magnetic fields, only Lorentz force is relevant,
that is, force acting on a moving charge. Time-varying
magnetic fields induce voltages (induction). Princi-
pally, in both cases the primary mechanism is the
same: relative movement of magnetic field lines and
the organ in question. In this case, time-varying fields
are used and the assumed effect is the generated
voltage via induction. Time-varying magnetic field
induces an electromotive force which is a voltage
around a closed loop through which the time-varying
magnetic flux goes. We can estimate the value of the
induced electric field by taking a loop having an equal
size than the coils (r¼ 70mm) just above the coil and
the amplitude of the flux density of 50mT at a
frequency of 100Hz. This will give a peak value of
0.48mV for the electromotive force, which corre-
sponds to an electric field of 1mV/m along the loop.
Typically, electric potentials in a human body are
some tens of millivolts and the corresponding dis-
tances from nanometers up to a millimeter. Even for a
distance of 1mm, the estimated electric field would
mean a potential difference of 1mV. For neuron sizes,
the induced potential difference would be several
orders of magnitude less. Therefore, it is evident that
a magnetic field equal to the Earth’s magnetic field
(50mT) at frequencies 10-n 100Hz is too low to
have clinically significant effects on a human body.
Regardless of the above-mentioned and assum-
ing that PEMF therapy increases capillary blood flow
in fibromyalgia, the question then arises of why
passive therapy should be used to increase circulation,
as it may not have an effect on tissue metabolism and
pain. It has been well established that exercise
increases microcirculation and tissue metabolism
[Shang et al., 2012], as well as having many other
benefits for health issues that may be of great concern
in patients with fibromyalgia. For instance, exercise
improves muscle strength and endurance, can help in
weight control, and improves mood and sleep [Kujala,
2009]. Active therapy modalities, such as land-based
aerobic [Busch et al., 2007] and resistance exercise
[Valkeinen et al., 2004; Busch et al., 2013] as well as
aquatic training [Tomas-Carus et al., 2008], have been
shown to improve function and relieve pain in patients
with fibromyalgia, and currently exercise is recom-
mended for the treatment of fibromyalgia in several
international guidelines [Ablin et al., 2013; Macfar-
lane et al., 2017]. The European League Against
Rheumatism (EULAR), in their updated management
recommendations, recently stated that exercise is the
only dependable therapy for the treatment of fibromy-
algia due to strong evidence for its effect on improve-
ments in pain and physical function [Macfarlane
et al., 2017].
This study has several strengths. First, we had a
randomized double-blinded placebo-controlled treat-
ment study with a long study duration. Second, all the
patients, outcome assessors, and statistician were
blinded to the treatment group assignment. Third, the
sample size was large enough and the crossover
design removed between patient variation [Yang and
Stufken, 2008]. Fourth, considering that high dropout
rates are a major issue with crossover design [Mills
et al., 2009], in this study the dropout rate was low
(8%) despite the relatively long duration of the study
(28 weeks).
There are some limitations that might have
influenced our study results. We used a crossover
design despite some of its known disadvantages,
specifically, period effect, and carryover effect [Alt-
man, 1991]. These methodological flaws, however,
were to some extent overcome in this study by
statistically adjusting for the period effect, and by
TABLE 2. Baseline, Change and Significance of Change Between Active and Sham Treatments
Active Sham
Baseline mean (SD) Change mean (95%CI) Baseline mean (SD) Change mean (95%CI) P
Pain, VAS 66 (22) 12 [18, 6] 63 (22) 11 [17, 5] 0.88
Stiffness, VAS 61 (26) 9 [15, 4] 59 (25) 11 [17, 5] 0.77
FIQ 47 (15) 5 [8, 2] 45 (14) 6 [9, 3] 0.57
SD, standard deviation; CI, confidence interval; VAS, visual analog scale; FIQ, Fibromyalgia Impact Questionnaire.
Adjusting for period effect.
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counterbalancing the time between the first and
second period sufficiently enough that the carryover
effect was not assumed.
CONCLUSIONS
This study revealed that low-energy pulsed
electromagnetic field treatment was no more effective
than treatment with a sham device in reducing pain
and stiffness or in improving functioning in women
with fibromyalgia. Thus, pulsed electromagnetic field
treatment cannot be recommended for treatment of
fibromyalgia symptoms.
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